Date:	_2022/9/15	
Your Name:	Yanyan Liu	
Manuscript Title:	_ A retrospective cohort study of polatuzumab vedotin combined with immunochemothe	erapy in
Chinese patients w	h relapse/refractory diffuse large B cell lymphoma	
Manuscript numbe	(if known):	
related to the cont	nsparency, we ask you to disclose all relationships/activities/interests listed below that a nt of your manuscript. "Related" means any relation with for-profit or not-for-profit third	
•	sts may be affected by the content of the manuscript. Disclosure represents a commitme does not necessarily indicate a bias. If you are in doubt about whether to list a	nt

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	5 Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
12	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	ase summarize the above co	nflict of interest in the follo	owing box:		
	lana				
'	None				

Date	e:2022/9/1	.5	
You	r Name: Zhijur	n Wuxiao	
Man	nuscript Title: A retrosp	ective cohort study of pola	atuzumab vedotin combined with immunochemotherapy in
Chin	ese patients with relapse/r	efractory diffuse large B ce	ell lymphoma
Man	nuscript number (if known):		
relat part to tr relat	ted to the content of your n ies whose interests may be ansparency and does not n tionship/activity/interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.
<u>man</u>	uscript only.		
to the med	ne epidemiology of hyperte lication, even if that medica	nsion, you should declare a ition is not mentioned in th port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting for	V. None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	V N			
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None			
′	meetings and/or travel	None			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options				
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dla					
Pie	Please summarize the above conflict of interest in the following box:				
	None				
'	NOTIC				
1					

:: Fanco	ng Kong	
t Title: A retrosp	ective cohort study of po	latuzumab vedotin combined with immunochemotherapy in
tients with relapse/r	efractory diffuse large B c	ell lymphoma
t number (if known):		
the content of your mose interests may be ency and does not no p/activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do	so.
ing questions apply to tonly.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
emiology of hyperten , even if that medica below, report all sup	nsion, you should declare tion is not mentioned in t port for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
	Name all entities with	Specifications/Comments
	relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
	Time frame: Since the initia	al planning of the work
port for the present cript (e.g., funding, on of study materials, al writing, article sing charges, etc.)	XNone	
e limit for this item.		
		t 36 months
tity (if not indicated	XNone	
	X None	
ting fees	XNone	
	tritle: A retrosp tients with relapse/ret number (if known): rest of transparency, the content of your mose interests may be rency and does not not provide a relationships/active emiology of hypertern, even if that medical below, report all suppare for disclosure is report for the present cript (e.g., funding, on of study materials, all writing, article sing charges, etc.) re limit for this item.	tritle: A retrospective cohort study of potients with relapse/refractory diffuse large B of number (if known):

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	, , , , , , , , , , , , , , , , , , ,		
6		XNone		
	testimony			
7	Support for attending	X None		_
'	meetings and/or travel	xnone		
8	Patents planned, issued or	XNone		_
	pending			
9	•	XNone		
	Safety Monitoring Board or			
	Advisory Board			
1	0 Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
1	1 Stock or stock options	X None		
-	Stock of Stock options			
1	2 Receipt of equipment,	X None		_
	materials, drugs, medical			_
	writing, gifts or other			
	services			
1	3 Other financial or non-	XNone		
	financial interests			
D	lease summarize the above co	inflict of interest in the fall	owing hov:	
۲	lease sullillarize the above co	milet of interest in the foll	owing box.	
	None			
	Hone			

Dat	e:2022/9/1	.5	
You	r Name: Jifeng	Feng	
Maı	nuscript Title: A retrosp	ective cohort study of pol	latuzumab vedotin combined with immunochemotherapy in
Chir	nese patients with relapse/r	efractory diffuse large B c	ell lymphoma
Maı	nuscript number (if known):		
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t	he epidemiology of hyperte dication, even if that medica	nsion, you should declare ition is not mentioned in t	
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	X None	an planning of the work
_	manuscript (e.g., funding, provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	V N			
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None			
′	meetings and/or travel	None			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options				
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dla					
Pie	Please summarize the above conflict of interest in the following box:				
	None				
'	NOTIC				
1					

Date	e:2022/9/1	.5	
	r Name: Jianqi		
Mar	nuscript Title: A retrosp	ective cohort study of pol	latuzumab vedotin combined with immunochemotherapy in
Chir	nese patients with relapse/r	efractory diffuse large B c	ell lymphoma
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to ti med In it	he epidemiology of hyperte dication, even if that medica	nsion, you should declare ation is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Tay 11 200 00	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 26 months
2	Grants or contracts from	X None	1. 30 Months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
	a lui c	V N	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	, , , , , , , , , , , , , , , , , , ,		
6		XNone		
	testimony			
7	Support for attending	X None		_
'	meetings and/or travel	xnone		
8	Patents planned, issued or	XNone		_
	pending			
9	•	XNone		
	Safety Monitoring Board or			
	Advisory Board			
1	0 Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
1	1 Stock or stock options	X None		
-	Stock of Stock options			
1	2 Receipt of equipment,	X None		_
	materials, drugs, medical			_
	writing, gifts or other			
	services			
1	3 Other financial or non-	XNone		
	financial interests			
D	lease summarize the above co	inflict of interest in the fall	owing hov:	
۲	lease sullillarize the above co	milet of interest in the foll	owing box.	
	None			
	Hone			

Date	e:2022/9/	15	
You	r Name: Zhihi	ua Yao	
Mar	nuscript Title: A retros	pective cohort study of pol	latuzumab vedotin combined with immunochemotherapy in
Chir	nese patients with relapse/	refractory diffuse large B c	ell lymphoma
Mar	nuscript number (if known)	:	
rela part to ti rela	ted to the content of your lies whose interests may be ransparency and does not i tionship/activity/interest,	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	
	following questions apply nuscript only.	to the author's relationship	ps/activities/interests as they relate to the <u>current</u>
to tl med In it	ne epidemiology of hyperto lication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	t 30 months
_	any entity (if not indicated		
_	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
•	22.734161118 1223		+

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None		_	
/	meetings and/or travel	xnone			
8	Patents planned, issued or	XNone		_	
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,			_	
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options	X_None			
				T	
12	Receipt of equipment,	X None		_	
	materials, drugs, medical			_	
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dlas	Please summarize the above conflict of interest in the following box:				
PIE	ase summanize the above co	miner of interest in the foll	owing box.		
N	lone				
'	10110				

Date	e:2022/9/1	.5	
	r Name: Weilun		
Man	nuscript Title: A retrosp	ective cohort study of pola	atuzumab vedotin combined with immunochemotherapy in
Chin	ese patients with relapse/r	efractory diffuse large B ce	ell lymphoma
Man	nuscript number (if known):		
relat part to tr relat	ted to the content of your n ies whose interests may be ansparency and does not n tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of list a so.
	uscript only.	o the duther of clationship	<u></u>
to the med	ne epidemiology of hyperte lication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items,
		A. II tu	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
	o lii t	V AI	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None		_	
/	meetings and/or travel	xnone			
8	Patents planned, issued or	XNone		_	
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,			_	
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options	X_None			
				T	
12	Receipt of equipment,	X None		_	
	materials, drugs, medical			_	
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dlas	Please summarize the above conflict of interest in the following box:				
PIE	ase summanize the above co	miner of interest in the foll	owing box.		
N	lone				
'	10110				

Date	e:2022/9/1	.5	
	r Name: Fei Li		
Mar	nuscript Title: A retrosp	ective cohort study of pola	atuzumab vedotin combined with immunochemotherapy in
Chir	ese patients with relapse/r	efractory diffuse large B ce	ell lymphoma
Mar	nuscript number (if known):		
rela part to ti rela	ted to the content of your r ies whose interests may be ansparency and does not n tionship/activity/interest, i	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	
	tollowing questions apply t	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to the med	ne epidemiology of hyperte lication, even if that medica	nsion, you should declare a ition is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items,
		At H .tst til	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	26 months
2	Grants or contracts from	X None	. So months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting for	V. None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None			
/	meetings and/or travel	xnone			
8	Patents planned, issued or	XNone		_	
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,			_	
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options	X_None			
				T	
12	Receipt of equipment,	X None		_	
	materials, drugs, medical			_	
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Dlas	Please summarize the above conflict of interest in the following box:				
PIE	ase summanize the above co	miner of interest in the foll	owing box.		
N	lone				
'	10110				